



**Notice Regarding the Commencement of Manufacturing and Sales of Neoantigen-Derived Peptides**

March 23, 2026

We are pleased to announce that REPROCELL Inc. (the "Company") has recently concluded a Master Service Agreement with HLB Pep Co., Ltd. (South Korea; hereinafter "HLB") and established a sales framework for the Japanese and global markets for neoantigen-derived peptides manufactured at HLB's GMP-compliant facilities.

As announced in our news release dated August 20, 2025, the Company launched "NeoSight," a neoantigen detection service designed to support the realization of personalized cancer immunotherapy, and this latest development represents a significant milestone in expanding the functionality of this service.

"NeoSight" is a service that conducts detailed analyses of the genetic information of individual patients' cancer tissues to identify patient-specific cancer cell markers (neoantigens). Through this service, we analyze the DNA and RNA of specimens (such as tumor tissues and blood) provided by customers, and by identifying patient-specific mutations, confirming their expression, and predicting MHC binding affinity based on HLA types, we propose optimal neoantigen sequences.

Through this collaboration with HLB, the Company has established a system to provide GMP-grade neoantigen-derived peptides based on the neoantigen sequences derived from each patient's unique cancer cells. This enables a one-stop framework that seamlessly covers everything from neoantigen detection to the manufacturing of GMP-grade peptides based on the detection results. These peptides can be widely utilized in research, translational research, and treatment design in clinical development for immune cell therapies, including personalized cancer vaccines and T-cell receptor (TCR) therapies, thereby strongly supporting the research, development, and clinical implementation of personalized cancer immunotherapy.

The direct impact of this matter on the Company's financial performance is expected to be minimal; however, we will promptly disclose any future events that may have a material impact on our business results.

## Glossary of Terms

- **Cancer Immunotherapy:** A therapeutic approach that activates a patient's own immune system to attack cancer, which includes immune checkpoint inhibitors, CAR-T/TCR therapies, and cancer vaccines. However, efficacy varies among individuals, and utilizing neoantigens—patient-specific targets—is considered crucial to overcoming these variations.
- **Neoantigen:** A novel peptide antigen arising from cancer-specific genetic mutations. The sequence varies for each patient and serves as a marker for immune cells to recognize and eliminate cancer. It is a target for personalized cancer vaccines and TCR therapies, and is also implicated in the efficacy of immune checkpoint inhibitors.
- **Personalized Medicine (Tailor-made Medicine):** The selection and implementation of the most appropriate treatment methods tailored to the individual constitution and disease type of each patient. It aims to provide more effective treatments with fewer side effects based on genetic information and other factors.

## About HLB Pep Co., Ltd.

HLB Pep Co., Ltd. is a South Korean biotechnology company with strengths in the development and manufacturing of peptide materials and peptide therapeutics, and is highly regarded, particularly for its rapid and accurate manufacturing technologies for high-purity peptides. The company is equipped with in-house GMP-compliant manufacturing facilities and has established a Contract Development and Manufacturing Organization (CDMO) framework for peptides as Active Pharmaceutical Ingredients (APIs), actively promoting business expansion into the field of personalized medicine in recent years.

For more details, please visit the following website: <https://hlbpep.co.kr/eng/main/>